37 patents
Page 2 of 2
Utility
Modified release preparations containing oxcarbazepine and derivatives thereof
9 Nov 21
Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed.
Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
Filed: 23 Apr 21
Utility
Stabilized Formulations of CNS Compounds
21 Oct 21
Formulations of molindone having superior stability and methods of administering same are provided.
Rong-Kun Chang, Michael L. Vieira, Likan Liang, Padmanabh P. Bhatt, Austin B. Huang, Sachin V. Patel
Filed: 25 Jun 21
Utility
CorrectedModified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
7 Oct 21
Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed.
Padmanabh P. BHATT, Argaw KIDANE, Kevin EDWARDS
Filed: 27 Oct 20
Utility
Methods of producing molindone and its salts
14 Sep 21
The present invention is directed towards novel methods of synthesis of molindone, synthesis of the intermediates of molindone, and high-purity compositions of molindone.
Martin Hanbauer, Zarghun Nazir, Peter Hildebrand, Attilia Figini, Likan Liang, Tiziano Fumagalli
Filed: 30 Apr 20
Utility
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
5 Aug 21
Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed.
Padmanabh P. BHATT, Argaw KIDANE, Kevin EDWARDS
Filed: 23 Apr 21
Utility
Stabilized formulations of CNS compounds
3 Aug 21
Formulations of molindone having superior stability and methods of administering same are provided.
Rong-Kun Chang, Michael L. Vieira, Likan Liang, Padmanabh P. Bhatt, Austin B. Huang, Sachin V. Patel
Filed: 30 Oct 18
Utility
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
11 Feb 21
Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed.
Padmanabh P. BHATT, Argaw KIDANE, Kevin EDWARDS
Filed: 27 Oct 20
Utility
Methods of Producing Molindone and Its Salts
19 Aug 20
The present invention is directed towards novel methods of synthesis of molindone, synthesis of the intermediates of molindone, and high-purity compositions of molindone.
Martin Hanbauer, Zarghun Nazir, Peter Hildebrand, Attilia Figini, Likan Liang, Tiziano Fumagalli
Filed: 29 Apr 20
Utility
Osmotic Drug Delivery System
19 Aug 20
An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
Argaw Kidane, Padmanabh P Bhatt
Filed: 19 Feb 20
Utility
Methods, System, and Kit for Monitoring, Diagnosing, and Treating Impulsive Aggression
5 Aug 20
The present disclosure relates to the treatment of impulsive aggression with molindone as an add-on therapy where patients are already receiving treatment for the underlying disease or disorder, e.g. attention deficit hyperactivity disorder (ADHD), bipolar disorder, autism, Tourette's syndrome or post traumatic stress disorder (PTSD), using evidence-based impulsive aggression testing methodologies and systems.
Jennifer DUGAN STOCKS, Christopher Evans, Seung Hwang, Susan M. Dallabrida
Filed: 16 Apr 20
Utility
Methods of producing molindone and its salts
8 Jun 20
The present invention is directed towards novel methods of synthesis of molindone, synthesis of the intermediates of molindone, and high-purity compositions of molindone.
Martin Hanbauer, Zarghun Nazir, Peter Hildebrand, Attilia Figini, Likan Liang, Tiziano Fumagalli
Filed: 20 Aug 18
Utility
Use of Higher Doses of Modified Release Huperzine Formulations
20 May 20
The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine.
Stephen D. COLLINS, Peter P. GOLDSTEIN, Joshua T. JOHNSTONE
Filed: 18 Nov 19
Utility
Method of Treatment of CNS Disorders
4 Mar 20
The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity.
Christopher D. Breder
Filed: 7 Nov 19
Utility
Method of Treatment of Aggression
22 Jan 20
The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.
Christopher D. BREDER
Filed: 3 Jan 19
Utility
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
18 Dec 19
Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed.
Padmanabh P. BHATT, Argaw KIDANE, Kevin EDWARDS
Filed: 17 Jan 19
Utility
Osmotic Drug Delivery System
6 Nov 19
An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
Argaw Kidane, Padmanabh P. Bhatt
Filed: 3 Dec 18
Utility
Methods for Producing Viloxazine Salts and Novel Polymorphs Thereof
2 Oct 19
Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof.
Likan LIANG, Padmanabh P. BHATT, David DAIN, Jean-Philippe TAQUET, Aleksandr PECHENOV, Alexei TCHESNOKOV, Reynold MARIAUX
Filed: 12 Nov 18